🇺🇸 FDA
Pipeline program

BI 3720931, Gadovist 1.0 mmol/ml solution for injection, Solvent for dilution for BI 3720931 inhaler solution, BI 3720931

1504-0001

Phase 2 small_molecule active

Quick answer

BI 3720931, Gadovist 1.0 mmol/ml solution for injection, Solvent for dilution for BI 3720931 inhaler solution, BI 3720931 for Cystic fibrosis is a Phase 2 program (small_molecule) at Boehringer Ingelheim International GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Boehringer Ingelheim International GmbH
Indication
Cystic fibrosis
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials